Therefore, in this study, we evaluated the combined effects of SMI and PD-1 inhibitors in a Lewis lung carcinoma (LLC) C57BL/6 and LUSC NCI-H226 humanized mouse model and explored the synergistic mechanisms of combined therapy using scRNA-seq to provide insights on PD-1 inhibitor/SMI combination therapy for NSCLC. Here, PDCD1 is linked to Carcinoma, Lewis Lung.